Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2954305 | 0.98 | CYP3A4 (0.55) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| SCHEMBL28704965 | 0.87 | CYP3A4 (0.65) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| 3,5-Dichloroanthranilic Acid SCHEMBL29557172 | 0.81 | AKR1C4 (0.61) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| SCHEMBL5886297 | 0.81 | CYP3A4 (0.70) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| 3,5-Dichloroanthranilic Acid SCHEMBL951092 | 0.81 | AKR1C4 (0.61) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| 3,5-Dichloroanthranilic Acid SCHEMBL11626235 | 0.79 | AKR1C4 (0.59) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| 3,5-Dichloroanthranilic Acid SCHEMBL28091744 | 0.79 | AKR1C4 (0.59) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| Hydrochloric Acid SCHEMBL11794608 | 0.79 | CYP3A4 (0.68) | CYP3A4CA1CA2AKR1C4AKR1C3 | |
| SCHEMBL12640756 | 0.78 | KDM4E (0.57) | CYP3A4CA1CA2ALDH1A1HPGD | |
| SCHEMBL4862551 | 0.78 | AKR1C2 (0.69) | CYP3A4CA1CA2AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7781430-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| CN-101160307-A | Benzoxazole carboxamides for the treatment of CINV and IBS-D | AMR TECHNOLOGY INC (US) | 2008-04-09 | — | — | CN | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1853597-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR Technology, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1415990-B1 | Diazepan derivatives useful as factor X inhibitor | ASTELLAS PHARMA INC (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006089100-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| CN-1226292-C | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2005-11-09 | — | — | CN | disclosed |
| EP-1415990-A1 | Diazepan derivatives useful as factor X inhibitor | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6642224-B1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
| CN-1319594-A | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2001-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195193-A1 | Diazepane derivatives or salts thereof | F10, F11, SERPINC1 | CYP3A4 1196/4885CA1 188/4885CA2 365/4885 |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | HTR3E, BRS3, HTR3A | CYP3A4 755/4885CA1 2263/4885CA2 1559/4885 |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | CYP3A4 755/4885CA1 2263/4885CA2 1559/4885 |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | F10, SERPINC1, F11 | CYP3A4 978/4885CA1 265/4885CA2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.